These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Lindenbaum Y; Kissel JT; Mendell JR Neurol Clin; 2001 Feb; 19(1):187-204. PubMed ID: 11471764 [TBL] [Abstract][Full Text] [Related]
49. Clinical significance of serum and CSF findings in the Guillain-Barré syndrome and related disorders. Segurado OG; Krüger H; Mertens HG J Neurol; 1986 Aug; 233(4):202-8. PubMed ID: 3746360 [TBL] [Abstract][Full Text] [Related]
50. Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Godelaine J; Chitale Y; De Moor B; Mathieu C; Ancheva L; Van Damme P; Claeys KG; Bossuyt X; Carpentier S; Poesen K Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37640545 [TBL] [Abstract][Full Text] [Related]
51. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. Kuitwaard K; Bos-Eyssen ME; Blomkwist-Markens PH; van Doorn PA J Peripher Nerv Syst; 2009 Dec; 14(4):310-5. PubMed ID: 20021573 [TBL] [Abstract][Full Text] [Related]
52. Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Chiang HL; Lyu RK; Tseng MY; Chang KH; Chang HS; Hsu WC; Kuo HC; Chu CC; Wu YR; Ro LS; Huang CC; Chen CM Clin Chim Acta; 2009 Jul; 405(1-2):143-7. PubMed ID: 19410571 [TBL] [Abstract][Full Text] [Related]
53. Class and IgG subclass distribution of antibodies against peripheral nerve myelin in sera from patients with inflammatory demyelinating polyradiculoneuropathy. Vedeler CA; Matre R; Nyland H Acta Neurol Scand; 1988 Nov; 78(5):401-7. PubMed ID: 2464267 [TBL] [Abstract][Full Text] [Related]
54. Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies. Illes Z; Blaabjerg M Handb Clin Neurol; 2017; 146():125-138. PubMed ID: 29110767 [TBL] [Abstract][Full Text] [Related]
55. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. van Doorn PA; Kuitwaard K; Jacobs BC J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496 [TBL] [Abstract][Full Text] [Related]
56. New-onset chronic inflammatory demyelinating polyradiculoneuropathy after COVID-19 infection: a case report. Abedi Samakoush M; Davoodi L; Khademian M; Kargar-Soleimanabad S; Abedini MA Ann Med Surg (Lond); 2023 Oct; 85(10):5031-5034. PubMed ID: 37811109 [TBL] [Abstract][Full Text] [Related]
57. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Draak TH; Vanhoutte EK; van Nes SI; Gorson KC; Van der Pol WL; Notermans NC; Nobile-Orazio E; Léger JM; Van den Bergh PY; Lauria G; Bril V; Katzberg H; Lunn MP; Pouget J; van der Kooi AJ; Hahn AF; Doorn PA; Cornblath DR; van den Berg LH; Faber CG; Merkies IS; Neurology; 2014 Dec; 83(23):2124-32. PubMed ID: 25378677 [TBL] [Abstract][Full Text] [Related]
58. Comparison of ultrasound findings in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy for differential diagnosis. Basiri K; Abdollahian M; Ghasemi M Curr J Neurol; 2021 Apr; 20(2):56-63. PubMed ID: 38011471 [No Abstract] [Full Text] [Related]
59. Impact of blood-brain barrier disruption on newly diagnosed neuromyelitis optica spectrum disorder symptoms and prognosis. Liang S; Qin Q; Tang Y; Liao W; Yang Y; He J; Li L Ann Palliat Med; 2020 Mar; 9(2):324-330. PubMed ID: 32268769 [TBL] [Abstract][Full Text] [Related]